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Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan- 
ErbB re-targeted CAR T-cells

Introduction
Malignant mesothelioma is a locally aggressive tumor that is primarily attributable to inhalation of asbestos fibers [1] , prompting stringent regulation of this mineral in many territories. Nonetheless, incidence continues to increase in many countries, reflecting the long latency period of disease progression [2] . Mesothelioma remains incurable with a median survival of 9 to 17 months [3, 4] .
Immunotherapy has long been posited as a logical approach to treat mesothelioma [5] .
Promising data have emerged from clinical trials of immune checkpoint blockade in this disease [6] . In parallel, there has been increasing interest in the development of adoptive immunotherapeutic approaches using genetically engineered T-cells. Chimeric antigen receptors (CARs) are bespoke fusion molecules that couple an antigen recognition element to a tailored signaling domain, thereby enabling the HLA independent retargeting of T-cell specificity [7] . Interest has been fueled by the repeated demonstration of unprecedented therapeutic efficacy when autologous CD19 targeted CAR T-cells are administered to patients with refractory acute lymphoblastic leukemia [8] . The most successful CAR configurations employ a second generation design in which CD28 or 4-1BB costimulatory modules are fused to CD3 [9] [10] [11] . While initial experience in patients with solid tumors has been disappointing, mesothelioma may represent a special case since tumors are amenable to regional CAR T-cell delivery to the affected body cavity. Preclinical data have provided strong support for this approach using CAR T-cells retargeted against mesothelin [12, 13] and fibroblast activation protein [14, 15] . Clinical trials employing both intra-pleural [16, 17] and systemic delivery [18] are ongoing.
An increasing concern with CAR T-cell immunotherapy is the emergence of therapeutic resistance due to target loss [19, 20] . This highlights the desirability of selecting multiple targets that contribute to disease pathogenesis and thus are subject to selective pressure for retention by tumors. In mesothelioma, the extended ErbB receptor family represents an attractive candidate to meet these requirements. Epidermal growth factor receptor (EGFR; ErbB1) is upregulated and phosphorylated in the majority of cases, compared to normal pleura [21] [22] [23] [24] [25] [26] [27] . Disappointingly however, clinical evaluation of EGFR tyrosine kinase inhibitors has proven ineffective in this disease [24, 25] , while trials involving EGFR inhibitory antibodies are ongoing (www.clinicaltrials.gov, accessed February 5 th , 2017). Co-expression of HER2 (ErbB2) [24, 28] has also been reported, although ErbB3 and ErbB4 have not previously been evaluated.
To redirect T-cell specificity against the ErbB family, we have engineered a second generation CAR named T1E28z. T1E28z engages 8 of 9 possible ErbB homo and heterodimers [29] and enables T-cells to elicit antitumor activity in preclinical models of ovarian, breast and head and neck cancers [29] [30] [31] . The CAR is co-expressed with a chimeric cytokine receptor named 4 that delivers an interleukin (IL)-2/IL-15 signal upon binding of IL-4, thereby enabling the selective enrichment of CAR T-cells during ex vivo expansion [32] . Importantly, culture of the resulting 'T4 + ' T-cells in IL-4 does not alter their differentiation and maintains type 1 polarity [32] . T4 immunotherapy is currently undergoing Phase 1 evaluation by intra-tumoral delivery in patients with head and neck cancer [33] . This approach has a further theoretical advantage in mesothelioma treatment since IL-4 is commonly found in the tumor microenvironment, providing an additional source of stimulation for T4 + T-cells [34] . Here, we tested the hypothesis that T4 + T-cells derived from patients with mesothelioma would exert meaningful antitumor activity against mesothelioma, justifying the clinical evaluation of this approach.
Materials and methods
Additional details are provided as an online supplement. 
Preparation of tissue microarray slides and immunohistochemistry of tumors
Genetic modification of patient T-cells
This study was approved by the Leeds West Research Ethics Committee (reference 12/YH/0392). Recombinant DNA constructs were expressed using the SFG retroviral vector. Retroviral transduction [35] and expansion of CAR T-cells using IL-4 was carried out as described [32] .
Cytotoxicity and cytokine release assays
Monolayers of mesothelioma cell lines were incubated with 1x10 6 T-cells overnight, (effector:target ratio of 1:1). Cytokine measurements were performed by ELISA. Tumor cell viability was assessed by MTT assay. 
Animal studies
RESULTS
Expression of ErbB receptors by malignant pleural mesotheliomas
Tissue microarrays were prepared from 168 malignant pleural mesotheliomas (MPM).
Histologic subtype was defined in 103 cases as epithelioid (56.7%), sarcomatoid (20.4%) or biphasic (22.8%). As expected [37] , survival was significantly longer for patients with epithelioid mesotheliomas, compared to other subtypes (Fig. 1A ).
Immunohistochemical analysis (Table I and (Table I) . Receptor distribution was mainly cytoplasmic (Supplementary Fig. S1 ).
Univariate analysis indicated that median patient survival was significantly influenced by EGFR expression status, but not by that of other ErbB family members (Fig. 1C) . Survival was shortest when tumors either lacked EGFR, or were strongly positive for EGFR expression ( Fig. 1C and Table II ). Similar findings were observed when analysis was restricted to tumors for which histologic subtype data were available (Table II and Fig. 1D ).
When restricted to epithelioid tumors, effect of EGFR expression on survival was no longer statistically significant ( Supplementary Fig. 2 ). Nonetheless, similar trends towards lower median survival were apparent when tumors either lacked EGFR or expressed EGFR at high levels (Table II) .
Multivariate analysis was undertaken to explore the interactive effects of EGFR and histologic status on patient survival. This demonstrated that histology remained a highly significant predictor of patient outcome. By contrast EGFR status was not a significant covariate, unless the analysis was restricted to the small number of tumors in which the highest level of EGFR positive was detected (Table III) .
CAR engineering of T-cells from mesothelioma patients
Given the prevalent expression of ErbB receptors in mesotheliomas, we explored feasibility of generation of T4 + T-cells using peripheral blood from mesothelioma patients.
All were male, aged 69.9+7.3 years (mean + SD) and had tumors of epithelioid (n=8), biphasic (n=2) or unspecified subtypes (n=2), at clinical stage T2N0 (n=6), T3N0 (n=5) or T4N2 (n=1). Blood was obtained prior to diagnostic surgery (n=10) or following chemotherapy (n=2). Control T-cells were transduced with SFG P4, which encodes for 4
and P28z [35] . P28z binds to PSMA, which is not expressed in mesothelioma.
Transduced CAR T-cells were selectively enriched by expansion in IL-4. 
In vitro assessment of antitumor activity of ErbB retargeted T-cells
Co-cultivation assays were performed in which patient derived CAR T-cells were incubated with a panel of mesothelioma cell lines (REN, JU77, LO68 and H28). Tumor cell lines expressed EGFR (Fig. 3A) , HER2 (Fig. 3B) and ErbB4 (Fig. 3D) , while low level expression of ErbB3 was detected in two cases (Fig. 3C) . All four mesothelioma cell lines were destroyed by T4 + , but not by control P4 + or untransduced T-cells (Fig. 4) . Activation of T4 + T-cells was indicated by release of significantly elevated amounts of IL-2 ( Fig. 5A ) and IFN- (Fig. 5B) .
In vivo assessment of patient derived ErbB retargeted CAR T-cells -single dose study
An i.p. xenograft model was established in SCID Beige mice using ffLuc/RFPexpressing LO68 cells. This approach was selected for three reasons. First, tumor progression models the propensity of mesothelioma to undergo intracavitary spread at a location in which human mesotheliomas also occur. Second, this model allowed us to examine the therapeutic activity and safety of patient derived T4 + T-cells, when delivered using a route that can cause cytokine release syndrome (CRS) [31] . Finally, i.p. delivery of tumor and T-cells is less traumatic to animals than intrapleural delivery.
Inoculation of either 0.5 or 2 million ffLuc + LO68 tumor cells led to engraftment followed by exponential tumor growth after 14 days (Supplementary Fig. S3 ). The higher (Fig. 6B ).
Repeated administration of patient-derived ErbB re-targeted CAR T-cells exerts superior therapeutic activity
We have recently shown that CAR T-cells are rapidly cleared from SCID Beige mice following i.p. delivery [38] . This contrasts to NSG mice where sustained engraftment leads to xenogeneic graft versus host disease (unpublished data). Consequently, we next explored the therapeutic efficacy and safety of repeated CAR T-cell dosing in the SCID Beige model. A 40mL blood sample was obtained from a patient with epithelioid MPM (patient 36) and CAR T-cells were engineered and expanded as above. Antitumor activity of T4 + but not control Tcells was confirmed using LO68 tumor cells ( Supplementary Fig. 4B ). CAR T-cells were adoptively transferred into tumor-bearing mice on days 14 and 21. Fig. 7A -B demonstrates that tumor regression was achieved in all T4 + T-cell treated mice, with disease eradication in safety profile [31] , with limited systemic absorption [39] . We have exploited this principle to initiate a clinical trial in which ErbB retargeted CAR T-cells are administered using the intratumoral route in patients with head and neck cancer [33] . To date, no dose limiting toxicities or evidence of systemic absorption of CAR T-cells has been observed in the first ten treated patients. Here, we demonstrate preclinical proof of concept for the utility of a related approach to treat mesothelioma. Mesothelioma is highly suited to intra-cavitary delivery since tumors are directly accessible using a pleural or peritoneal catheter [12, 16, 40] .
We first profiled ErbB receptor expression in a large tumor series. The majority of MPM expressed EGFR, in agreement with previous reports [21] [22] [23] [24] [25] [26] [27] . Expression of EGFR has previously been linked to no alteration [21, 23, 25] or to improved survival of mesothelioma patients on univariate analysis [22, 27] . In agreement, we found that lack of EGFR was associated with shortened patient survival. Since this effect lost significance when the analysis was restricted to epithelioid tumors, it may in part reflect the tendency of poorer prognosis mesothelioma subtypes (notably sarcomatoid tumors) [41] to lack EGFR expression. Notably however, we also observed that in EGFR positive tumors, highest level expression was also linked to shortened survival. Although not been described previously, a similar trend was seen in a smaller study in which intensity of EGFR expression by mesotheliomas was ranked [21] .
Expression of HER2 has previously been examined in mesothelioma, with divergent findings. Our finding that HER2 is infrequently detectable using immunohistochemistry is consistent with Garland et al. [24] , but not with an earlier report in which 97% of tumors were positive [28] . In interpreting these findings, differing sensitivities of distinct immunohistochemical approaches should be considered.
We also undertook an evaluation of ErbB3 and ErbB4 expression by MPM, building on earlier studies using immortalized cell lines [42] [43] [44] . While ErbB3 was not detected, about half of tumors expressed ErbB4. Once again, the limited sensitivity of immunohistochemistry should be considered in interpreting these findings. Nonetheless, these data indicate that several ErbB dimer species recognized by the T1E28z CAR are present in most mesotheliomas, notably epithelioid tumors.
Immunotherapy using CAR T-cells generally involves the use of an autologous product. Consequently, it was imperative to demonstrate feasibility of transduction and expansion of patient-derived CAR T-cell products. To facilitate this, T1E28z was co- . Reassuringly however, no such toxicity was evident at the doses of CAR T-cells used here.
In conclusion, we have demonstrated ErbB receptor expression in most mesotheliomas, particularly of the epithelioid subtype. Exploiting this, human ErbB- 
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